Comparing mirabegron and solifenacin for treating overactive bladder in women
Comparisons of the Impact of Beta-3 Agonist Versus Antimuscarinics on Psychological Distress, Sexual Function, Bladder Wall Thickness and Blood Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study.
This study is testing whether the medications mirabegron or solifenacin can better help women with overactive bladder feel better and improve their quality of life.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 20 Years and up |
| Sex | Female |
| Sponsor | Far Eastern Memorial Hospital Academic / other |
| Locations | 1 site (Banqiao, New Taipei) |
| Trial ID | NCT04023253 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of two medications, mirabegron and solifenacin, on various aspects of overactive bladder syndrome in women. It specifically looks at psychological distress, sexual function, bladder wall thickness, and bladder blood flow. Participants will receive either medication to determine which is more effective in alleviating symptoms and improving quality of life. The study is designed as a Phase 3 interventional trial to provide robust data on the comparative effectiveness of these treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are women diagnosed with overactive bladder syndrome.
Not a fit: Patients with allergies to mirabegron or solifenacin, or those with severe comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for women suffering from overactive bladder syndrome.
How similar studies have performed: Other studies have shown varying degrees of success with similar medications for overactive bladder, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Overactive bladder syndrome Exclusion Criteria: * Allergy to mirabegron or solifenacin. * Patients with severe hypertension who are difficult to control, known urethral diverticulum, known bladder malignant tumors, urinary retention patients, gastric retention patients, uncontrolled angular glaucoma patients, dialysis patients, severe renal dysfunction , moderate liver dysfunction, use strong inhibitors of CYP3A4 such as ketoconazole.
Where this trial is running
Banqiao, New Taipei
- Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital — Banqiao, New Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Sheng-Mou Hsiao, MD
- Email: smhsiao2@gmail.com
- Phone: +886289667000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.